Cited by 367Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Open access
Aguirre, Andrew J., Nowak, Jonathan A., Camarda, Nicholas D., Moffitt, Richard A., Ghazani, Arezou A., Hazar-Rethinam, Mehlika, Raghavan, Srivatsan, Kim, Jaegil +53 more·2018·Cancer Discovery

Published version of a preprint

Abstract

Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alterations were identified in 48% (34/71) and pathogenic/likely pathogenic germline alterations in 18% (13/71) of patients. Overall, 30% (21/71) of enrolled patients experienced a change in clinical management as a result of genomic data. Twenty-six patients had germline and/or somatic alterations in DNA-damage repair genes, and 5 additional patients had mutational signatures of homologous recombination deficiency but no identified causal genomic alteration. Two patients had oncogenic in-frame BRAF deletions, and we report the first clinical evidence that this alteration confers sensitivity to MAPK pathway inhibition. Moreover, we identified tumor/stroma gene expression signatures with clinical relevance. Collectively, these data demonstrate the feasibility and value of real-time genomic characterization of advanced PDAC. Significance: Molecular analyses of metastatic PDAC tumors are challenging due to the heterogeneous cellular composition of biopsy specimens and rapid progression of the disease. Using an integrated multidisciplinary biopsy program, we demonstrate that real-time genomic characterization of advanced PDAC can identify clinically relevant alterations that inform management of this difficult disease. Cancer Discov; 8(9); 1096–111. ©2018 AACR. See related commentary by Collisson, p. 1062. This article is highlighted in the In This Issue feature, p. 1047

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-0275

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Alternative drivers are found in 8-10% of PDAC cases that are KRAS wild type.

    “there are also so-called “alternative drivers” found in the 8–10% of cases that are KRAS wild type104,105.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [105]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., Welch, M. W., Reilly, E., McCabe, D., Marini, L., Anderka, K., Helvie, K., Oliver, N., Babic, A., Da Silva, A., Nadres, B., Van Seventer, E. E., Shahzade, H. A., St. Pierre, J. P., Burke, K. P., Clancy, T., Cleary, J. M., Doyle, L. A., Jajoo, K., McCleary, N. J., Meyerhardt, J. A., Murphy, J. E., Ng, K., Patel, A. K., Perez, K., Rosenthal, M. H., Rubinson, D. A., Ryou, M., Shapiro, G. I., Sicinska, E., Silverman, S. G., Nagy, R. J., Lanman, R. B., Knoerzer, D., Welsch, D. J., Yurgelun, M. B., Fuchs, C. S., Garraway, L. A., Getz, G., Hornick, J. L., Johnson, B. E., Kulke, M. H., Mayer, R. J., Miller, J. W., Shyn, P. B., Tuveson, D. A., Wagle, N., Yeh, J. J., Hahn, W. C., Corcoran, R. B., Carter, S. L., & Wolpin, B. M.
Affiliations
  • Broad Institute (US)
  • Brigham and Women's Hospital (US)
  • Stony Brook University (US)
  • Massachusetts General Hospital (US)
  • Dana-Farber Cancer Institute (US)
  • 1Dana-Farber Cancer Institute, Boston, Massachusetts.
  • 9Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Guardant (United States) (US)
  • 14BioMed Valley Discoveries, Kansas City, Missouri.
  • Harvard University (US)
  • Cold Spring Harbor Laboratory (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
  • Aguirre, Andrew J.
  • Carter, Scott L.
  • Wolpin, Brian M.
Venue
Cancer Discovery
Published
2018-09-01
Volume
8
Issue
9
Pages
1096-1111
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2808191072
Cited by
367
References
55
Citations by year
2026: 17 · 2025: 38 · 2024: 38 · 2023: 48 · 2022: 58 · 2021: 70 · 2020: 52 · 2019: 34 · 2018: 10
FWCI
15.56
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
Funders
  • Lustgarten Foundation
  • Noble Effort Fund
  • Peter R. Leavitt Family Fund
  • Wexler Family Fund
  • Promises for Purple
  • HHS | NIH | National Cancer Institute (NCI) (P50CA127003, U01CA224146, U01CA210171, R01CA199064, K08CA2118420-01)
  • Pancreatic Cancer Action Network (PanCAN)
  • Hale Center for Pancreatic Cancer Research, Dana-Farber Cancer Institute
  • Hope Funds for Cancer Research
  • Doris Duke Charitable Foundation (DDCF)
  • Conquer Cancer Foundation (CCF)
  • Broman Fund for Pancreatic Cancer Research
  • Harvard Clinical and Translational Sciences Center (UL1 TR001102)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
pancreatic ductal adenocarcinoma, advanced pancreatic cancer, precision medicine, exome sequencing, RNA sequencing, germline alterations, somatic alterations, DNA repair genes, homologous recombination deficiency, mutational signatures, MAPK inhibition, biopsy protocol, metastatic cancer
MeSH terms
Exome Sequencing, Adult, Aged, Aged, 80 and over, DNA Repair, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Genetic Variation, Gene Expression Regulation, Neoplastic, Sequence Analysis, RNA, Germ-Line Mutation, Gene Expression Profiling, MAP Kinase Signaling System, Carcinoma, Pancreatic Ductal, Genomics, Gene Regulatory Networks, Precision Medicine, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review